Medtronic’s Strong Financial Performance and Promising Growth Outlook Justify Buy Rating

Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Medtronic (MDT – Research Report). The associated price target remains the same with $95.00.

Josh Jennings has given his Buy rating due to a combination of factors including Medtronic’s strong financial performance and promising growth outlook. The company reported revenue and earnings per share (EPS) that surpassed market expectations, with organic sales growth reaching 5.4%, higher than the consensus estimate of 4.6%. This consistent growth, marked by ten consecutive quarters of mid-single-digit organic revenue increases, highlights Medtronic’s robust market position.
Furthermore, Medtronic’s guidance for future growth remains optimistic, with an anticipated 5% organic sales growth for fiscal 2026, exceeding Street expectations. Despite a projected EPS outlook slightly below consensus due to tariff impacts, the company expects to achieve high single-digit EPS growth in fiscal 2027. This outlook is supported by anticipated revenue growth, favorable foreign exchange conditions, and strategic benefits from the planned separation of its Diabetes division.

In another report released today, Citi also maintained a Buy rating on the stock with a $98.00 price target.